1253056-18-6 Usage
Description
Sitagliptin DeaMino IMpurity 1, also known as 3-Desamino-2,3-dehydro Sitagliptin, is an impurity found in Sitagliptin (S491000), a trizolopyrazine dipeptidyl peptidase IV inhibitor. Sitagliptin has been approved for the therapy of type II diabetes and plays a crucial role in managing blood sugar levels in patients.
Uses
Used in Pharmaceutical Industry:
Sitagliptin DeaMino IMpurity 1 is used as an impurity in the production of Sitagliptin for the treatment of type II diabetes. The presence of this impurity is essential for the development and formulation of Sitagliptin, as it contributes to the overall effectiveness of the drug in managing blood sugar levels.
Sitagliptin DeaMino IMpurity 1 is used as a research compound for the study of its potential effects on the DPP-IV enzyme, which is involved in the regulation of blood glucose levels. Understanding the interactions and effects of this impurity can provide valuable insights into the development of more effective treatments for type II diabetes.
Additionally, Sitagliptin DeaMino IMpurity 1 can be used as a reference material for quality control and analytical testing in the pharmaceutical industry. This ensures the purity and efficacy of Sitagliptin, as well as the safety and reliability of the drug for patients.
Check Digit Verification of cas no
The CAS Registry Mumber 1253056-18-6 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,5,3,0,5 and 6 respectively; the second part has 2 digits, 1 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 1253056-18:
(9*1)+(8*2)+(7*5)+(6*3)+(5*0)+(4*5)+(3*6)+(2*1)+(1*8)=126
126 % 10 = 6
So 1253056-18-6 is a valid CAS Registry Number.
1253056-18-6Relevant articles and documents
EXPEDIENT SYNTHESIS OF SITAGLIPTIN
-
Paragraph 00371; 00373, (2015/09/23)
Novel intermediates are disclosed as intermediates for preparation of a Sitagliptin. A novel synthetic method to prepare Sitagliptin using the said intermediates is also disclosed.